Bristol-Myers Squibb Welcomes NICE Guidance Recommending Baraclude As Chronic Hepatit
NICE (National Institute for Health and Clinical Excellence) has published guidance that recommends Baraclude(R) (entecavir) as an option for treatment of eligible patients with chronic hepatitis B (CHB).